English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/201497
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Emerging role of microRNAs in dilated cardiomyopathy: evidence regarding etiology

AuthorsCalderon-Dominguez, María; Belmonte, Thalia; Quezada-Feijoo, Maribel; Ramos-Sánchez, Mónica; Fernandez-Armenta, J.; Pérez-Navarro, Amparo; Cesar, Sergi; Peña-Peña, María Luisa; Vea, Ángela; Llorente-Cortés, Vicenta; Mangas, Alipio; Gonzalo-Calvo, David de; Toro, Rocío
KeywordsBiomarker
Cardiomyopathy
Dilated cardiomyopathy
Heart failure
microRNA
Issue DateJan-2020
PublisherElsevier BV
CitationTranslational Research - the Journal of Laboratory and Clinical Medicine 215: 86-101 (2019)
AbstractDilated cardiomyopathy (DCM) is a heart muscle disease characterized by ventricular dilation and systolic dysfunction in the absence of abnormal loading conditions or coronary artery disease. This cardiac disorder is a major health problem due to its high prevalence, morbidity, and mortality. DCM is a complex disease with a common phenotype but heterogeneous pathological mechanisms. Early etiological diagnosis and prognosis stratification is crucial for the clinical management of the patient. Advances in imaging technology and genetic tests have provided useful tools for clinical practice. Nevertheless, the assessment of the disease remains challenging. Novel noninvasive indicators are still needed to assist in decision-making. microRNAs (miRNAs), a group of small noncoding RNAs, have been identified as key mediators of cell biology. They are found in a stable form in body fluids and their concentration is altered in response to stress. Previous research has suggested that the miRNA signature constitutes a novel source of noninvasive biomarkers for a wide array of cardiovascular diseases. Specifically, several studies have reported the potential role of miRNAs as clinical indicators among the etiologies of DCM. However, this field has not been reviewed in detail. Here, we summarize the evidence of intracellular and circulating miRNAs in DCM and their usefulness in the development of novel diagnostic, prognostic and therapeutic approaches, with a focus on DCM etiology. Although the findings are still preliminary, due to methodological and technical limitations and the lack of robust population-based studies, miRNAs constitute a promising tool to assist in the clinical management of DCM.
Publisher version (URL)http://dx.doi.org/10.1016/j.trsl.2019.08.007
URIhttp://hdl.handle.net/10261/201497
Identifiersdoi: 10.1016/j.trsl.2019.08.007
issn: 1878-1810
issn: 1931-5244
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
Art Rev DCM miRNAs Rev1 DdGC 190819 unmarked.pdf Embargoed until August 23, 2020498,95 kBAdobe PDFThumbnail
View/Open    Request a copy
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.